Research Progress on Clinical Diagnosis, Treatment, and Drug Resistance Mechanisms of T-Cell Lymphoma
CAO Yi, QIU Liyun, ZHANG Yuchen, CAI Jun, CAI Qingqing*
TCL (T-cell lymphoma) is a subtype of non-Hodgkin lymphoma characterized by high heterogeneity and aggressiveness. In recent years, with the advancements in precision medicine, single-cell sequencing, and multi-omics analysis, significant progress has been made in understanding the diagnosis, staging, and treatment strategies for T-cell lymphoma. This paper reviews the epidemiology, diagnosis, clinical treatment, and drug resistance mechanisms of T-cell lymphoma, with a focus on PTCL (peripheral T-cell lymphoma), ENKTL (extranodalnatural killer T-cell lymphoma), and other rare subtypes. Additionally, it explores the mechanisms of drug resistance in T-cell lymphoma, including multidrug resistance, tumor microenvironment and immune evasion, and the abnormal activation of signaling pathways. The integration of emerging technologies and the development of targeted therapies are expected to further improve the clinical outcomes for T-cell lymphoma patients.
CN
EN